Ferguson Wellman Capital Management Inc. cut its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 6.8% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 9,453 shares of the financial services provider’s stock after selling 685 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in iShares Biotechnology ETF were worth $1,298,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. BNP Paribas Financial Markets boosted its holdings in shares of iShares Biotechnology ETF by 25.7% in the first quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock valued at $282,038,000 after buying an additional 420,053 shares during the period. Global Assets Advisory LLC acquired a new position in iShares Biotechnology ETF in the 1st quarter worth $66,059,000. Commonwealth Equity Services LLC increased its holdings in iShares Biotechnology ETF by 5.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 198,709 shares of the financial services provider’s stock worth $27,267,000 after purchasing an additional 10,033 shares in the last quarter. Raymond James & Associates raised its stake in shares of iShares Biotechnology ETF by 5.3% in the 1st quarter. Raymond James & Associates now owns 181,835 shares of the financial services provider’s stock valued at $24,951,000 after purchasing an additional 9,073 shares during the period. Finally, Raymond James Financial Services Advisors Inc. lifted its holdings in shares of iShares Biotechnology ETF by 13.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 174,225 shares of the financial services provider’s stock valued at $23,907,000 after purchasing an additional 20,533 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors.
iShares Biotechnology ETF Stock Down 0.7 %
Shares of NASDAQ:IBB traded down $0.96 during mid-day trading on Wednesday, reaching $142.59. 509,624 shares of the stock were exchanged, compared to its average volume of 1,597,239. The stock’s 50 day simple moving average is $140.73 and its 200-day simple moving average is $136.60. iShares Biotechnology ETF has a one year low of $111.83 and a one year high of $150.17.
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Stocks That Could Beat the September Blues
- 5 discounted opportunities for dividend growth investors
- Canopy Growth Stock: Can It Sustain Recent Gains?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.